Maureen McMahon, MD
Rheumatology · Los Angeles, CANPI 1285655852
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $251,713 of the $374,009 with a category attached, or 67.3%. 8 manufacturers reported payments, led by GSK at 50.5% of the total. 2025 is the largest year on record at $81,132, 2.3 times the $35,461 reported in 2019. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $1400.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$189K
- AstraZeneca$122K
- Aurinia Pharma U.S., Inc.$27K
- Eli Lilly$23K
- Genentech, Inc.$7K
- E.r. Squibb & Sons, L.L.C.$4K
- plus $2K from 2 others
Across 74 payments — averaging $10,244 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$348K
- E.r. Squibb & Sons, L.L.C.$173K
- Amgen$80K
- GSK$70K
- Astrazeneca UK Limited$47K
- Sanofi US Services Inc.$28K
- plus $10K from 1 others
What the payments were for
- Consulting fees$96,11626%
- Speaking & faculty fees$251,71367%
- Travel & lodging$19,9525%
- Food & beverage$6,2102%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 114 | $188,714 |
| AstraZeneca | 103 | $121,989 |
| Aurinia Pharma U.S., Inc. | 28 | $27,114 |
| Eli Lilly | 12 | $22,570 |
| Genentech, Inc. | 7 | $7,330 |
| E.r. Squibb & Sons, L.L.C. | 1 | $4,400 |
| Amgen | 1 | $1,800 |
| Novartis | 1 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$374,009 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 40 | $298,650 |
| OtezlaApremilast | 19 | $90,896 |
| Humira(Cf) PenAdalimumab | 13 | $87,222 |
| BenlystaBelimumab | 12 | $55,117 |
| Hydroxychloroquine Sulfate | 80 | $3,399 |
| MethotrexateMethotrexate Sodium | 41 | $1,826 |
| Azathioprine | 21 | $1,151 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $928 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 30 | $854 |
| Prednisone | 102 | $697 |
| Gabapentin | 28 | $202 |
| Amlodipine Besylate | 11 | $77 |
| Citalopram HbrCitalopram Hydrobromide | 13 | $2 |
| Lisinopril | 12 | $0 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $1,800 | $90,89619 claims |
| GSKBenlysta | $188,714 | $55,11712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in Los Angeles
- Haoling WengLos Angeles$562K
- Glenn EhresmannLos Angeles$450K
- Elizabeth VolkmannLos Angeles$400K
- Daniel ArkfeldLos Angeles$378K
- Leanna WiseLos Angeles$286K
- Jon GilesLos Angeles$248K
- Christina Charles-SchoemanLos Angeles$231K
- Karina Marianne TorralbaLos Angeles$142K
- Thomas RomanoLos Angeles$131K
- Gary FeldmanLos Angeles$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.